Analysts Anticipate Beam Therapeutics Inc (NASDAQ:BEAM) to Post -$0.54 EPS

Analysts expect Beam Therapeutics Inc (NASDAQ:BEAM) to report ($0.54) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Beam Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($0.58). The company is scheduled to issue its next quarterly earnings results on Tuesday, August 11th.

On average, analysts expect that Beam Therapeutics will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($2.77) to ($2.48). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.70) per share, with EPS estimates ranging from ($3.20) to ($2.13). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Beam Therapeutics.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.48). The firm had revenue of $0.01 million for the quarter.

Beam Therapeutics stock opened at $19.34 on Monday. Beam Therapeutics has a 12-month low of $13.00 and a 12-month high of $31.80. The company’s fifty day moving average is $25.50.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on Beam Therapeutics (BEAM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with's FREE daily email newsletter.